Myeloperoxidase in the diagnosis of acute coronary syndromes: The importance of spectrum

W. Frank Peacock, John Nagurney, Robert Birkhahn, Adam Singer, Nathan Shapiro, Judd Hollander, Ted Glynn, Richard Nowak, Basmah Safdar, Chadwick Miller, Mary Peberdy, Francis Counselman, Abhinav Chandra, Joshua Kosowsky, James Neuenschwander, Jon Schrock, Stephen Plantholt, Elizabeth Lewandrowski, Vance Wong, Ken KupferDeborah Diercks

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Background: Myeloperoxidase (MPO) is proposed for risk stratification in patients with suspected acute coronary syndromes (ACSs). We determined if MPO has diagnostic value in patients being evaluated for ACS. Method: MIDAS was an 18-center prospective study enrolling suspected ACS emergency department patients who presented <8 hours after symptom onset and in whom serial cardiac markers and objective cardiac perfusion testing were planned. Blinded MPO (Biosite, Inc, San Diego, CA) and troponin I (Triage Cardio 3; Biosite, Inc) were drawn at arrival, and Troponin I (TnI) was measured at 90, 180, and 360 minutes. Final diagnoses were adjudicated by the local investigator blinded to study assay. Results: Of 1,018 patients, 54% were male, 26% black, with a mean age of 58 ± 13 years. Diagnoses were ACS in 288 (23%) and noncardiac chest pain (NCCP) in 788 (77%). Of patients with ACS, 94 (9.2%) had a myocardial infarction (MI) at presentation (69 non-ST-elevation MI, 25 ST-elevation MI), and 136 had unstable angina. Using a cutpoint of 210 ng/mL to provide 90% specificity, MPO had a sensitivity of 0.18; negative predictive value, 0.69; positive predictive value, 0.47; negative likelihood ratio, 0.91; and a positive likelihood ratio of 1.83 to differentiate ACS and NCCP. Because of the large overlap of quartiles, MPO was not clinically useful to predict serial TnI changes. The C statistics ± 95% CI for MPO differentiating ACS from NCCP and for AMI versus NCCP were 0.629 ± 0.04 and 0.666 ± 0.06, respectively. Conclusions: Myeloperoxidase has insufficient accuracy for decision making in patients with suspected ACS.

Original languageEnglish (US)
Pages (from-to)893-899
Number of pages7
JournalAmerican Heart Journal
Volume162
Issue number5
DOIs
StatePublished - Nov 1 2011

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Myeloperoxidase in the diagnosis of acute coronary syndromes: The importance of spectrum'. Together they form a unique fingerprint.

  • Cite this

    Peacock, W. F., Nagurney, J., Birkhahn, R., Singer, A., Shapiro, N., Hollander, J., Glynn, T., Nowak, R., Safdar, B., Miller, C., Peberdy, M., Counselman, F., Chandra, A., Kosowsky, J., Neuenschwander, J., Schrock, J., Plantholt, S., Lewandrowski, E., Wong, V., ... Diercks, D. (2011). Myeloperoxidase in the diagnosis of acute coronary syndromes: The importance of spectrum. American Heart Journal, 162(5), 893-899. https://doi.org/10.1016/j.ahj.2011.08.017